Skip to main content

Table 1 Baseline demographics and characteristics of the patients with AS

From: Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial

Information Kunxian (n = 35) Placebo (n = 33)
Demographics
 Male, n (%) 32 (91.4) 30 (90.9)
 Age, years (SD) 27.19 (7.94) 28.83 (7.09)
Disease characteristics
 Symptom duration in years 6.76 (5.47) 7.98 (4.78)
 Concomitant NSAID, n (%) 13 (37.1) 15 (45.5)
Clinical features, n (%)
 Inflammatory back pain 32 (91.4) 32 (97.0)
 Elevated CRP (>3 mg/liter) 31 (88.6) 24 (72.7)
 Elevated ESR (male >20; female >15 mm/h) 32 (91.4) 29 (87.9)
Disease activity
 ASDAS-CRP 3.36 (1.06) 3.41 (1.00)
 BASDAI (0–10) 4.79 (1.45) 4.82 (1.22)
 Total back pain (0–10) 5.09 (2.69) 5.34 (2.58)
 Global assessment (0–10) 5.18 (2.08) 5.90 (1.85)
 Swollen joints, range 0–44 0.46 (1.48) 0.29 (1.1)
 Tender joints, range 0–44 5.57 (4.96) 4.91 (3.37)
 BASFI (0–10) 3.10 (2.00) 2.80 (2.00)
 Inflammation/morning stiffness (0–10) 4.79 (2.79) 5.2 (2.43)
 ESR (mm/h) 36.95 (25.26) 35.79 (31.46)
 CRP (mg/liter) 29.5 (29.93) 27.50 (29.69)
 BASMI (0–10) 2.88 (1.95) 3.75 (1.99)
  1. All values are expressed as mean (SD) unless otherwise indicated
  2. Abbreviations: NSAID nonsteroidal anti-inflammatory drugs, CRP C-reactive protein, ESR erythrocyte sedimentation rate, ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, VAS visual analog scale, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index